Delcath Expands MultiCenter Phase III Trial for Metastatic Melanoma

Delcath Systems, Inc. announced that the University of Texas Medical Branch at Galveston (UTMB), part of the University of Texas System, has joined Delcath's Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the company's Percutaneous Hepatic Perfusion (PHP) System for the isolated, high-dose delivery of the anti-cancer agent melphalan.
CNN Money